Harm-benefit Tradeoff
Harm-Benefit Tradeoff is a normative decision-making construct in risk-benefit assessment that evaluates the balance between potential harms and anticipated benefits by determining whether the magnitude or likelihood of adverse outcomes is ethically and pragmatically justifiable relative to the expected gains.
102
Publications
6.7K
Citations
400
Authors
257
Institutions
Publications per year
2017–2026
47
Parents
102
Reducing Inappropriate Polypharmacy
Ian Scott, Sarah N. Hilmer, Emily Reeve et al. · JAMA Internal Medicine · 2015 · 1.5K citations · Full text
1–5 of 102
400
5
h-index
4
h-index
3
h-index
3
h-index
3
h-index
1–5 of 400
257

The University of Sydney
Sydney, Australia
10 h-index
36 publications
8.9K citations
University College London
London, United Kingdom
5 h-index
13 publications
1.3K citations
University of Washington
Seattle, United States
4 h-index
4 publications
182 citations
Fred Hutch Cancer Center
Seattle, United States
4 h-index
8 publications
664 citations
The George Institute for Global Health
Sydney, Australia
4 h-index
11 publications
507 citations

The University of Queensland
Brisbane, Australia
4 h-index
5 publications
3.2K citations
University of Wisconsin–Madison
Madison, United States
4 h-index
14 publications
1.3K citations
University of Zurich
Zurich, Switzerland
3 h-index
5 publications
79 citations
1–8 of 257
MDM · 4 publications · 285 citations
4
h-index
3 publications · 222 citations
3
h-index
3 publications · 196 citations
3
h-index
3 publications · 235 citations
3
h-index
2 publications · 31 citations
2
h-index
1–5